List of investigational obsessive–compulsive disorder drugs
Jump to navigation
Jump to search
This is a list of investigational obsessive–compulsive disorder drugs, or drugs that are currently under development for clinical use in the treatment of obsessive–compulsive disorder (OCD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Under development
Actively under development
- Immunoglobulin (immune globulin 10%, 10% high purity immunoglobulin, 10% IVIG, NewGam, Newnorm, Octagam 10%, Octagam, Panzyga) – immunoglobulin / immunostimulant [1][1]
- Troriluzole (BHV-4157, BHV-4157a, FC-4157; trigriluzole) – prodrug of riluzole / glutamate modulator [2][1]
Preclinical development
- Cannabis extracts (various) – cannabinoid receptor modulators [3]
No development reported
- 4'-Fluorocannabidiol (4'-F-CBD; fluorinated cannabidiol; HUF-101, HUF-102, HUF-103) – cannabinoid receptor modulator, other actions [4]
- AbbVie/Rugen research programme – unspecified mechanism of action [5]
- Agomelatine (Alodil, Melitor, Thymanax, Valdoxan, Vestin; AGO-178, AGO178C, S-20098, S-20098-F55) – serotonin 5-HT2C receptor antagonist and melatonin receptor agonist [6]
- CR-5542 – orexin receptor antagonist [7]
- Dual SSRIs and serotonin 5-HT1A receptor agonists (SSA-426, WAY-163426, WAY-211612, WAY-253752, WAY-426) [8]
- Risperidone (Risperdal, Risperdal Consta, Risperdal Depot; JNJ-410397-AAA, R-64766, R064766) – atypical antipsychotic / monoamine receptor modulator [9]
- Secretin (SecreFlo; INN-329, RG-1068) – hormone/diagnostic agent [10]
- Sosei Heptares research programme – various mechanisms of action [11]
Not under development
Development discontinued
- Bitopertin (R-1678, RG-6718, RG1678, RO-4917838) – glycine GlyT1 inhibitors / glycine reuptake inhibitor [12]
- Cycloserine (D-cycloserine; TIK-101) – glutamate NMDA receptor partial agonist [13]
- Elzasonan (CP-448187, CP-448187-01) – serotonin 5-HT1B and 5-HT1D receptor antagonist
- F-14258 – serotonin 5-HT1B and 5-HT1D receptor antagonist
- Fluoxetine/naltrexone (OREX-004) – selective serotonin reuptake inhibitor and opioid receptor antagonist [14]
- Mavoglurant (AFQ-056) – glutamate mGlu5 receptor antagonist [15]
- NPL-2003 – glutamate modulator [16]
- Ondansetron (Setrodon; TO-2061) – serotonin 5-HT3 receptor antagonist [17][1]
- RO-600175 – serotonin 5-HT2C receptor agonist [18]
- Roxindole (EMD-49980) – dopamine receptor agonist, serotonin receptor modulator, adrenergic receptor modulator, and serotonin reuptake inhibitor [19]
- SB-200646 (SB-200646A) – serotonin 5-HT2B and 5-HT2C receptor antagonist [20]
Formal development never or not yet started
- 5-HT6 receptor agonists (e.g., WAY-181187, WAY-208466)[2]
- Antiandrogens (e.g., flutamide, cyproterone acetate, triptorelin)[3]
- Cannabinoids (e.g., nabilone, tetrahydrocannabinol (THC)/cannabis) – cannabinoid receptor modulators[1]
- NMDA receptor modulators (e.g., ketamine, memantine, nitrous oxide, rapastinel)[1]
- Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., celecoxib, naproxen) – cyclooxygenase inhibitors[1]
- Rituximab (Rituxan) – monoclonal antibody against CD20[1]
- Serotonergic psychedelics (e.g., psilocybin/psilocybin mushrooms, lysergic acid diethylamide (LSD)) – serotonin receptor modulators[4][5][6][7][1]
- Tolcapone (Tasmar) – catechol-O-methyltransferase inhibitor[1]
Clinically used drugs
Approved drugs
- Clomipramine (Anafranil) – tricyclic antidepressant / monoamine reuptake inhibitor and receptor modulator [21]
- Escitalopram (S-citalopram; Cipralex, Entact, Lexapro, Seroplex, Sipralex, Sipralexa; LU-26054; MLD-55) – selective serotonin reuptake inhibitor [22]
- Fluoxetine (Prozac, Prozac Weekly, Reneuron, Sarafem; LY-110140) – selective serotonin reuptake inhibitor [23][24]
- Fluvoxamine (Depromel, Luvox, Luvox CR; SME-3110) – selective serotonin reuptake inhibitor and sigma-1 receptor agonist [25]
- Paroxetine (Aropax, Deroxat, Divarius, Dropax, Dropaxin, Frosinor, Motivan, Paxil, Paxil CR, Serestill, Seroxat, Tagonis; BRL-29060, BRL-29060A, FG-7051, NNC-207051, SI-211103) – selective serotonin reuptake inhibitor [26][27]
- Sertraline (Aremis, Besitran, Gladem, J Zoloft, Lustral, Serad, Serlain, Tatig, Zoloft; CP-51974, CP-51974-01) – selective serotonin reuptake inhibitor [28]
Off-label drugs
- Atypical antipsychotics (e.g., aripiprazole, olanzapine, quetiapine, risperidone) – monoamine receptor modulators
See also
References
- ^ a b c d e f g h i Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". J Exp Pharmacol. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.
- ^ Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt MR, Dawson LA, Cole D, Bernotas R, Robichaud A, Rosenzweig-Lipson S, Beyer CE (May 2008). "Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466". Neuropsychopharmacology. 33 (6): 1323–35. doi:10.1038/sj.npp.1301503. PMID 17625499.
- ^ Nomani H, Mohammadpour AH, Moallem SM, YazdanAbad MJ, Barreto GE, Sahebkar A (2020). "Anti-Androgen Drugs in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review". Curr Med Chem. 27 (40): 6825–6836. doi:10.2174/0929867326666191209142209. PMID 31814547. S2CID 208956450.
- ^ Moreno FA, Wiegand CB, Taitano EK, Delgado PL (November 2006). "Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder". J Clin Psychiatry. 67 (11): 1735–40. doi:10.4088/jcp.v67n1110. PMID 17196053.
- ^ Andersen KA, Carhart-Harris R, Nutt DJ, Erritzoe D (February 2021). "Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies". Acta Psychiatr Scand. 143 (2): 101–118. doi:10.1111/acps.13249. PMID 33125716. S2CID 226217912.
- ^ Odland AU, Kristensen JL, Andreasen JT (March 2021). "Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice". Behav Brain Res. 401: 113093. doi:10.1016/j.bbr.2020.113093. PMID 33359368. S2CID 229690041.
- ^ Castro Santos H, Gama Marques J (2021). "What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review". Porto Biomed J. 6 (1): e128. doi:10.1097/j.pbj.0000000000000128. PMC 8055489. PMID 33884324.
Further reading
- Berlin HA, Hamilton H, Hollander E (2008). "Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments". Mt Sinai J Med. 75 (3): 174–203. doi:10.1002/msj.20045. PMID 18704978.
- Marazziti D, Dell'Osso L (April 2015). "Why have early investigational therapies of obsessive-compulsive disorder failed to materialise?". Expert Opin Investig Drugs. 24 (4): 455–8. doi:10.1517/13543784.2015.1005735. PMID 25599971.
- Grassi G, Cecchelli C, Vignozzi L, Pacini S (2020). "Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder". J Exp Pharmacol. 12: 695–706. doi:10.2147/JEP.S255375. PMC 7801912. PMID 33447096.